Current Editions

BeOne reports six-year data from Brukinsa in front-line CLL and early results from a BTK degrader that anchors a broader protein degradation strategy

Oral STAT6 program shows biologics-like biomarker activity in Phase Ib atopic dermatitis study, sending biotech’s shares up 42%

A coherent suite of α-synuclein, NfL, GFAP and DaT-SPECT findings points to the possibility of disease modification

Headwinds have dampened momentum, yet the underlying scientific potential remains as compelling as ever

Non-covalent molecules move into treatment-naive patients, while degraders provide an option to combat resistance

Aleniglipron shows up to 15% weight loss, but tolerability remains key question

Yale spinout launches AI-integrated, whole-brain perfusion platform to de-risk CNS therapies

Because the FDA commissioner is making regulatory decisions, his views about scientific evidence are concerning

Five new drugs and vaccines recommended at committee’s December meeting

Retatrutide’s 26.6% weight loss is the most yet at 68 weeks, perhaps too much for some patients

BioCentury’s translational roundup also highlights a drawback of strong PD-1 inhibition, Neovacs’ allergy vaccine, and a female inflammation driver

Biosecure 2.0, FIGHT China Act intend to reduce reliance on Chinese biotechs

Dispute over reforms has prevented Congress from reauthorizing the SBIR/STTR programs

The FDA commissioner endorses conspiracy theories 

Plus: Long-acting obesity therapeutics play Prolynx draws $70M series A, and more

All but one upsized their offerings